Precision for Medicine and Trialbee Partner to Advance Clinical Trials for Complex Therapies and Speed Shift Toward Precision Medicine
5.8.2021 16:00:00 EEST | Business Wire | Press release
Clinical research organization Precision for Medicine and Trialbee, a patient matching and enrollment platform, are addressing complexities in clinical development through a new partnership that will accelerate the future of precision medicine. Trialbee’s advanced analytics will play a critical role in matching patients to trials conducted by Precision for Medicine and extending recruitment to a more diverse, targeted patient community for the development of complex, personalized medicine.
The partnership expands Precision for Medicine’s ability to match patients who could benefit from life-saving therapies, especially those who could be a match for trials in oncology, rare and orphan diseases, including cell or gene therapy trials. Trialbee enables accurate and fast enrollment, improving the patient journey and helping to meet patient enrollment timelines.
The Precision Site Network, which includes both academic and non-academic sites across North America, Europe, and Australia, can combine with Trialbee’s targeting data to identify untapped populations for trials. This outreach, which can be geotargeted to trial candidates close to that site, greatly enhances patient enrollment with a focus on representative trial participants.
Trialbee HIVE™ is a real-world data-driven patient matching platform that accelerates recruitment using global data assets, look-alike modeling, and digital outreach. Then, interested participants are qualified and enrolled through a nurse qualification process and patient centric experience.
Both companies are industry leaders in applying technology and data science to help clinical research sponsors succeed in the development of life-changing therapies. Precision has comprehensive study experience in complex therapeutic area and a converged approach to development that includes seamless operations between labs, data, and trials.
“We are working with life science innovators who share a passion to connect next generation treatments with the patients who need them most,” said Precision for Medicine President, Chad Clark. “This partnership expands our ability to reach more patients, faster; particularly those with rare or difficult-to-treat diseases.”
Precision for Medicine and Trialbee also reduce the burden on patients and sites. Trialbee’s patient data, which is HIPPA compliant, includes socioeconomic data as well as clinical data, enabling better characterization of the patient population. This helps Precision for Medicine forecast situations in which decentralized clinical trial approaches may be implemented to accommodate work schedules or when the use of free transportation services to and from the site can increase enrollment and retention.
“Our combined capabilities support a patient-first approach that will expand diversity, bolster enrollment, and speed the development of new therapies for complex diseases,” said Trialbee’s CEO, Matt Walz. “Our ability to bring more transparency and easy communication to the well-established Precision framework improves the potential for life-saving drugs to get to market and improve patient outcomes.”
About Precision for Medicine
Precision for Medicine is the first biomarker-driven clinical research services organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively. Precision applies novel biomarker approaches to clinical research that integrate clinical trial execution with deep scientific knowledge, laboratory expertise and advanced data sciences. This convergence of trials, labs and data sciences is driving faster clinical development and approval. Precision for Medicine is part of Precision Medicine group with over 2,500 people in 35 locations in the U.S., Canada, and Europe. For more information, visit http://www.precisionformedicine.com.
About Trialbee
Trialbee is the leading global data and technology platform for patient matching and enrollment in clinical trials. Trialbee Hive™ operationalizes real world data (RWD) and applies data science to match patients globally. Our Candidate Manager platform simplifies the journey for matched patients to qualify and participate in clinical research. Partnering with Sponsors, CROs and virtual/decentralized sites and software providers, Trialbee is achieving patient enrollment goals and driving enhancements in diversity in clinical trial populations. We are the smartest way to match and enroll patients for your clinical trial. For more information, visit http://www.trialbee.com or contact us at solutions@trialbee.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210805005145/en/
Contact information
Rosina Ferrante
Gregory FCA (for Trialbee)
215-344-2113
rosina.ferrante@trialbee.com
Louis Landon
Precision Medicine Group
310 984 7707
louis.landon@precisionvh.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma Initiates Phase I Clinical Trial in Australia Evaluating ME3241, an Anti-PD-1 Agonist Antibody Discovered Through Collaborative Research With FBRI12.3.2026 08:00:00 EET | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) announced today that it has initiated a Phase I clinical trial of ME3241 (development code), an anti-PD-1 agonist monoclonal antibody discovered through collaborative research with the Foundation for Biomedical Research and Innovation at Kobe (Headquarters: Kobe, Japan; President: Shuh Narumiya; hereinafter “FBRI”). The Phase I clinical trial is designed as a randomized, placebo-controlled, double-blind study, with the objective of evaluating the safety and tolerability of ME3241 following single and multiple dosing, as well as its pharmacokinetics and pharmacodynamics (ClinicalTrials.gov: NCT07422207). ME3241 was discovered through a collaborative research program led by Program Director Tasuku Honjo, a professor emeritus at Kyoto University. PD-1 is a molecule expressed on activated T cells and other lymphocytes that suppresses immune responses. Through this re
Redslim expands into Asia-Pacific to support global brands with data and AI infrastructure12.3.2026 08:00:00 EET | Press release
Redslim, a specialist in end-to-end data management solutions and an Astorg portfolio company, today announced its expansion into the Asia-Pacific region and the appointment of Kyriakos Zannikos as Regional Director, APAC. The move marks an important milestone in Redslim’s global growth strategy and brings the company closer to clients operating in one of the world’s fastest-growing and most data-driven consumer markets. As global consumer brands accelerate digital transformation and AI adoption, many organizations still struggle with fragmented data ecosystems spanning multiple agencies, markets and datasets. These challenges are particularly pronounced in Asia-Pacific, where diverse market structures and rapid growth create complex data environments. Redslim helps organizations transform fragmented market information into valuable data assets, empowering clients to make confident decisions and unlock the full value of their data. By building strong data foundations, Redslim supports
EIG’s MidOcean Energy to Acquire Additional Gorgon LNG Interest from JERA; Parties Explore Strategic Alliance12.3.2026 04:14:00 EET | Press release
MidOcean Energy (“MidOcean”), a liquefied natural gas (LNG) company formed and managed by EIG, today announced it has entered into definitive agreements with JERA Co., Inc. (“JERA”) to acquire JERA Gorgon Pty Ltd, which holds JERA’s 0.417% interest in the Gorgon LNG project. MidOcean is an existing participant in the Gorgon LNG project, and this transaction increases MidOcean’s interest in Gorgon to 1.417%. The transaction perimeter also includes JERA’s 0.735% interest in the Ichthys LNG project. Subject to the satisfaction of relevant conditions precedent, the interests in Gorgon and Ichthys will be sold to MidOcean, and then the Ichthys interest shall be transferred, subject to the satisfaction of further conditions, to an existing joint venture participant in the Ichthys LNG project. The acquisition increases MidOcean’s equity exposure to a large-scale, long-life, integrated LNG project operated by Chevron, further strengthening its portfolio of high-quality producing assets. In par
DCX Launches Comprehensive ECDU Portfolio – Enterprise-Class Coolant Distribution Units From 600 kW to 2.6 MW11.3.2026 17:34:00 EET | Press release
DCX Liquid Cooling Systems today unveiled its new ECDU (Enterprise Coolant Distribution Unit) platform, a family of three purpose-built CDU models that deliver real cooling capacities from 600 kW to 2.6 MW in industry-standard rack and in-row footprints. The portfolio has been engineered specifically for the accelerating transition to direct-to-chip liquid cooling in high-density enterprise, colocation, cloud, and hyperscale AI environments where thermal stability, uptime, and cost-efficiency are non-negotiable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260311214891/en/ DCX ECDU, the new generation of Enterprise Coolant Distribution Units dedicated to HPC and AI deployments. The lineup consists of: Enterprise ECDU 1380/2600 V1 - Delivers 1.38–2.6 MW of actual cooling capacity (based on real-world secondary-loop conditions). Single-pump configuration reaches flow rates up to 3,333 liters per minute (lpm). Mission Critica
Laserfiche Earns 5-Star Rating in the 2026 CRN® Partner Program Guide11.3.2026 16:00:00 EET | Press release
Laserfiche — the leading SaaS provider of intelligent content management — has been honored by CRN®, a brand of The Channel Company, with a 5-Star Award in the 2026 CRN Partner Program Guide. This annual guide is an essential resource for partners seeking vendor partner programs that match their business goals and deliver high partner value. As organizations navigate growing pressure to increase productivity and respond to regulatory change, Laserfiche’s AI-powered document management solutions enable users to transform operations and achieve meaningful business results at scale. Partners that innovate with Laserfiche solutions have the opportunity to grow profits through the Laserfiche Partner Program, which equips them with the tools and resources needed to deliver customer success. Laserfiche’s partner ecosystem drives sustainable growth, delivers differentiated solutions and maximizes opportunities for both partners and their customers. Laserfiche provides comprehensive AI and clou
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom